Fig. 4: 2nd PFS in patients achieving an OIFI ≥ 4 months (a) or <4 months (b) according to treatment received after progression to first-line FOLFOXIRI/Bev.
Bev bevacizumab, CI confidence interval.
Fig. 4: 2nd PFS in patients achieving an OIFI ≥ 4 months (a) or <4 months (b) according to treatment received after progression to first-line FOLFOXIRI/Bev. | British Journal of Cancer
